« Back
The EurOPDX EDIReX project: towards a European Research Infrastructure on patient-derived cancer models
The EurOPDX EDIReX project: towards a European Research Infrastructure on patient-derived cancer models
Submitted on 09 Nov 2018

E. Vinolo 1, J.P. Morris 1, D.G. Alférez 2, J. Arribas 3,4,5, C. Bernadó 3,4,5, A. Bertotti 6, A. Bruna 7, A.T. Byrne 8, C. Caldas 7, R.B. Clarke 2, N. Conte 9, R. Corsi 10, S. Corso 6, M. Crespo 3, A. Dahmani 11, V. Dangles-Marie 11, D. Decaudin 11, Z. Dudová 12, A. Fiori 6, S. Giordano 6, M. Hauptsmann 13, M. Hidalgo 14, C. Isella 6, S. de Jong 15, J. Jonkers 13, A. Křenek 12, O. Krijgsman 13, D. Kouřil 12, J.C. Lacal 14, L. Lanfrancone 16, E. Leucci 17, G.M. Mælandsmo 18, E. Marangoni 11, J. Mason 9, M.Th. Mayrhofer 19, A. Mazzocca 6, T.S. Meehan 9, E. Montaudon 11, F. Nem
1 seeding science sprl, Limelette, Belgium; 2 Manchester Cancer Research Center, University of Manchester, UK; 3 Vall d'Hebron Institute of Oncology, Barcelona, Spain; 4 Universitat Autònoma de Barcelona, Bellaterra, Spain; 5 Institució Catalana de Recerca I Estudis Avançats (ICREA), Barcelona, Spain; 6 Universitof Torino, Candiolo Cancer Institute IRCCS, Candiolo, Italy; 7 Cancer Research UK Cambridge Institute, Cambridge Cancer Centre, UK; 8 Royal College of Surgeons in Ireland, Dublin, Ireland; 9 EMBL-European Bioinformatics Institute, Hinxton, UK; 10 Kairos 3D srl, Turin, Italy; 11 Institut Curie, Paris, France; 12 Masarykova Univerzita, Brno, Czech Republic; 13 Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, The Netherlands; 14 Hospital Universitario de Fuenlabrada, Madrid, Spain; 15 University Medica
This poster was presented at 30th EORTC-NCI-AACR SYMPOSIUM (ENA2018) Dublin, Ireland, 13th - 16th Novemver 2018
Poster Views: 464
View poster »
Poster Abstract
Counteracting high failure rates in the development of new treatment strategies in oncology and improving therapeutic management of cancer patients requires preclinical models that can account for the complexity and heterogeneity of human tumours. Patient-derived cancer xenografts (PDXs) are developed by transplanting tumour fragments into immunodeficient mice. They maintain histopathological features and genetic profiles of the original patient tumours and are increasingly recognised as reliable models to predict treatment efficacy and discover sensitivity and resistance biomarkers with immediate clinical relevance.

To effectively recapitulate and therapeutically interrogate the heterogeneity of human cancer, a dozen European cancer centres and university hospitals involved in translational oncology joined forces in 2013 to start EurOPDX, an academic research consortium that now gathers 18 institutions throughout Europe and in the US ( The goal of the Consortium is to maximize exploitation of PDXs and other patient-derived models for cancer research by: (i) integrating institutional collections into a multicentre repository now reaching more than 1500 models for 30+ different cancer types; (ii) defining common standards to improve the quality and reproducibility of oncology preclinical data; (iii) sharing models within and outside the consortium to perform collaborative precision oncology “xenopatient” trials. Building on its first successes, EurOPDX is now teaming up with other key academic and SME partners in a four-year project to build the “EurOPDX Distributed Infrastructure for Research on patient-derived Xenografts" (EDIReX project funded under EU’s H2020 research and innovation programme, grant no. 731105).

This new cutting-edge European infrastructure will offer access to PDX resources for academic and industrial cancer researchers through 6 state-of-the-art installations or “nodes”. We will present the specific objectives of the project, including our work towards standardisation and optimisation of biobanking, quality control and data tracking, and the performance of in vivo drug efficacy experiments. Access to the resource, including the distribution of cryopreserved samples from established models, the structured biobanking of user-developed models and the performance of drug efficacy studies, will be offered through a grant application system to open in October 2018. Selection of the models by users will be made possible thanks to the newly-developed EurOPDX Data Portal, of which a prototype will be presented.

Through the EDIReX project we aim to improve preclinical and translational cancer research and promote innovation in oncology by integrating a European PDX repository and facilitating access to this much-needed resource for European and worldwide researchers.

Report abuse »
Ask the author a question about this poster.
Ask a Question »

Creative Commons

Related Posters

Strategies for High-Titer Protein Expression Using the ExpiCHO and Expi293 Transient Expression Systems
Chao Yan Liu, Jian Liu, Wanhua Yan, Kyle Williston, Katy Irvin, Henry Chou, Jonathan Zmuda

A Chemically-Defined Baculovirus-Based Expression System for Enhanced Protein Production in Sf9 Cells
Maya Yovcheva, Sara Barnes, Kenneth Thompson, Melissa Cross, Katy Irvin, Mintu Desai, Natasha Lucki, Henry Chiou, Jonathan Zmuda

Development of an in vitro Model System for Newcastle Disease Virus Persistence in Bladder Cancer Cells
Ahmad U1,, Chan SC2, Chau DM1, Chia SL5, Abdullah S1,3, Yusoff K5 & Veerakumarasivam A1,4*

Localisation of HN Gene Expression of NDV-AF2240 in Brain of 4T1 Induced Breast Cancer BALB/c mice
Umar Ahmad, Gholamreza Motalleb, Asmah Rahmat, Fauziah Othman, & Aini Ideris

Salamanca Grosso, G.; Osorio Tangafarife, M.P.